welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
NIH Awards $86 Million to Improve Genome Editing Techniques
Somatic Cell Genome Editing support is aimed at improving therapeutic options for both rare and common diseases.
Making changes to a patients DNA can have powerful implications for the treatment of disease. To tap into this immense potential, NIH recently awarded 21 Somatic Cell Genome Editing grants — totaling approximately $86 million over the next five years, pending available funds — to support research aimed at improving methods to edit the human genome. These grants are the first to be awarded through the Somatic Cell Genome Editing (SCGE) program, which was launched in January 2018 with NIH Common Fund support. As a trans-NIH endeavor, SCGE is managed by staff from multiple NIH Institutes and Centers, with leadership from NCATS.
rareRelated
-
Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyTo evaluate the long-term safety and tol...
-
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
-
Acceptance and Commitment Therapy for Muscle DiseaseIn adults, muscle diseases are usually c...
-
Ketoacidosis in Duchenne muscular dystrophy: A report on 4 casesThe longer survival in Duchenne dystroph...
-
Can a drug cure genetic disease? | Steve Wilton | TEDxPerthhttps://youtu.be/qgfwOuvMLrE...
-
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
-
New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology...PTC Therapeutics, Inc. today announced t...
